股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 華領醫藥 | | | | | | 呈交日期: | 2026年2月5日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 2,000,000,000 | USD | 0.001 USD | | 2,000,000 | | 增加 / 減少 (-) | | | USD | | | | 本月底結存 | 2,000,000,000 | USD | 0. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 華領醫藥 | | | 呈交日期: | 2026年1月7日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.001 USD | | 2,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD ...

北部湾港 矽电股份 中直股份 兴福电子 吉贝尔 华资实业 莱特光电 华领医药 福莱新材 赛力斯 创新奇智 ...

Core Viewpoint - The "Annual Outstanding Biopharmaceutical Company" award was presented to Hualing Pharmaceutical-B (02552.HK) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by Gelonghui on December 22 [1] Group 1 - The award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications in the biopharmaceutical field [1] - The evaluation criteria for the award include technological innovation, research and development strength, and the ability to translate results into practical applications [1]

12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选 中，百利天恒(688506.SH)、东阳光药(06887.HK)、东曜药业-B(01875.HK)、和铂医药-B(02142.HK)、华领医药-B(02552.HK)、先声药业(02096.HK)、亚盛 医药(06855.HK/AAPG.US)、真实生物8家企业荣获"年度卓越生物医药企业"奖项。（排名不分先后，按公司首部字母顺序排列） "年度卓越生物医药企业"是从技术创新、研发实力、成果转化等多方面综合评估，旨在表彰在生物医药领域具有自主核心技术、持续创新并能高效将科研成 果转化为临床或商业应用的领军企业。本次评选通过定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角兽公司排行榜。此次"金格奖"上市公司评选覆盖港交 所、上交所、深交所、纽交所、美国证券交易所、纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 ...

"年度卓越生物医药企业"是从技术创新、研发实力、成果转化等多方面综合评估，旨在表彰在生物医药领域具有自主核心技术、持续创新并能高效将科研成 果转化为临床或商业应用的领军企业。本次评选通过定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角兽公司排行榜。此次"金格奖"上市公司评选覆盖港交 所、上交所、深交所、纽交所、美国证券交易所、纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选 中，百利天恒(688506.SH)、东阳光药(06887.HK)、东曜药业-B(01875.HK)、和铂医药-B(02142.HK)、华领医药-B(02552.HK)、先声药业(02096.HK)、亚盛 医药(06855.HK/AAPG.US)、真实生物8家企业荣获"年度卓越生物医药企业"奖项。（排名不分先后，按公司首部字母顺序排列） ...

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3%, currently at 3.25 HKD, following the announcement of the successful administration of the first patient in a multi-dose escalation (MAD) Phase Ib trial for HMS1005, a second-generation glucose kinase activator [1][2]. Group 1: Clinical Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) subjects in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1]. Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow for once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1]. - The drug aims to improve the repair capacity of patients with insufficient GLP-1 secretion [1]. Group 3: Future Plans - Following the successful completion of the MAD Ib study, the company plans to seek partners for the global development of HMS1005 [2].

Core Viewpoint - 华领医药-B (02552.HK) experienced a price increase of over 3%, reaching HKD 3.25 with a trading volume of HKD 3.303 million [2] Group 1 - The stock rose by 3.17% as of the time of reporting [2] - The current trading price is HKD 3.25 [2] - The total trading volume recorded is HKD 3.303 million [2]

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3% following the successful administration of the first patient in the MAD Ib trial of its second-generation glucose kinase activator (GKA), HMS1005, in the United States [1][2] Group 1: Trial Details - The MAD Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) patients in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1] Group 2: Drug Characteristics - HMS1005 is a new molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and increasing the duration of the drug's action in the intestine [2] - The company has previously completed and published results from a single-dose escalation study of HMS1005, confirming its feasibility for once-daily oral treatment in T2D and obesity patients [2] Group 3: Future Plans - Following the successful completion of the MAD Ib trial, the company plans to seek partners for the global development of HMS1005 [2]

Group 1 - The core viewpoint of the news is that HuaLing Pharmaceutical has successfully completed the first dosing of its second-generation glucose kinase activator (GKA) HMS1005 in a Phase Ib multiple ascending dose (MAD) trial in the United States, marking a significant step in expanding its presence in the overseas diabetes market [1][2] - HMS1005 is designed as a novel molecular entity with improved physicochemical properties, featuring a sustained-release formulation that allows for once-daily dosing, enhancing patient convenience and potentially improving adherence to treatment [1] - The successful completion of the Phase Ib clinical trial will lead the company to seek partnerships for the global market development of HMS1005, further solidifying its leading position in the global GKA sector [1] Group 2 - The CEO of HuaLing Pharmaceutical, Dr. Chen Li, emphasized that the initiation of the Phase Ib clinical trial in the U.S. is a critical step in leading the innovation of diabetes drug development and overseas market expansion [2] - The company aims to validate the safety and tolerability of the second-generation GKA through robust trial design and strong R&D execution, laying a solid foundation for future clinical development [2] - HuaLing Pharmaceutical is committed to exploring better treatment options while deepening its existing product market, with plans to continue advancing more innovative drugs and global outreach to provide new treatment hopes for patients with type 2 diabetes [2]